These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27398060)

  • 21. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement.
    Chiang CY; Pan CH; Hsieh CH; Tsai JP; Chen MY; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
    PLoS Negl Trop Dis; 2013; 7(9):e2432. PubMed ID: 24069487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on dengue vaccine development, challenges, and future perspectives.
    Idris F; Ting DHR; Alonso S
    Expert Opin Drug Discov; 2021 Jan; 16(1):47-58. PubMed ID: 32838577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dengue vaccines: challenges, development, current status and prospects.
    Ghosh A; Dar L
    Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flaviviruses and flavivirus vaccines.
    Heinz FX; Stiasny K
    Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relevance of dengue virus genotypes surveillance at country level before vaccine approval.
    Usme-Ciro JA; Méndez JA; Laiton KD; Páez A
    Hum Vaccin Immunother; 2014; 10(9):2674-8. PubMed ID: 25483495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress towards a dengue vaccine.
    Webster DP; Farrar J; Rowland-Jones S
    Lancet Infect Dis; 2009 Nov; 9(11):678-87. PubMed ID: 19850226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges for the formulation of a universal vaccine against dengue.
    Chokephaibulkit K; Perng GC
    Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development.
    Wilder-Smith A; Ooi EE; Vasudevan SG; Gubler DJ
    Curr Infect Dis Rep; 2010 May; 12(3):157-64. PubMed ID: 21308524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Potential Impact of Vaccination on the Dynamics of Dengue Infections.
    Knipl D; Moghadas SM
    Bull Math Biol; 2015 Dec; 77(12):2212-30. PubMed ID: 26585748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dengue vaccine design: issues and challenges.
    Cardosa MJ
    Br Med Bull; 1998; 54(2):395-405. PubMed ID: 9830205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dengue fever: theories of immunopathogenesis and challenges for vaccination.
    Remy MM
    Inflamm Allergy Drug Targets; 2014; 13(4):262-74. PubMed ID: 25163973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.
    Züst R; Toh YX; Valdés I; Cerny D; Heinrich J; Hermida L; Marcos E; Guillén G; Kalinke U; Shi PY; Fink K
    J Virol; 2014 Jul; 88(13):7276-85. PubMed ID: 24741106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dengue vaccines approach the finish line.
    Edelman R
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S56-60. PubMed ID: 17582571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity.
    Izmirly AM; Alturki SO; Alturki SO; Connors J; Haddad EK
    Front Immunol; 2020; 11():1055. PubMed ID: 32655548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dengue infection and advances in dengue vaccines for children.
    Halstead SB; Dans LF
    Lancet Child Adolesc Health; 2019 Oct; 3(10):734-741. PubMed ID: 31378686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review on Dengue Vaccine Development.
    Deng SQ; Yang X; Wei Y; Chen JT; Wang XJ; Peng HJ
    Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32024238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immune responses to dengue virus infection: lessons learned from prospective cohort studies.
    Endy TP
    Front Immunol; 2014; 5():183. PubMed ID: 24795725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue viruses and promising envelope protein domain III-based vaccines.
    Fahimi H; Mohammadipour M; Haddad Kashani H; Parvini F; Sadeghizadeh M
    Appl Microbiol Biotechnol; 2018 Apr; 102(7):2977-2996. PubMed ID: 29470620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of antibody concentration as the main parameter in a dengue virus antibody-dependent enhancement assay using FcγR-expressing BHK cells.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Arch Virol; 2014 Jan; 159(1):103-16. PubMed ID: 23900750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.